Evan Seigerman

Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. But, the biotech company, renowned for its cancer and HIV treatments, has not positioned itself as a contender in this lucrative field. Most recently,...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met its primary and secondary endpoints, which attracted investments from whales. Raymond...

A successful COVID-19 vaccine could be a bumper revenue opportunity for the pharmaceutical companies, with the market estimated to generate at least $10 billion in revenue a year, according to analysts. The Thesis: Morgan Stanley and Credit Suisse analysts estimate that people will...

The biotech sector is a surefire winner due to a two-pronged benefit from the coronavirus pandemic, according to an analyst at Credit Suisse.  Biotechs To Outperform In Q2? The biotech sector is not only the likely source of the solution to the pandemicm but is also fairly...

Biogen Inc (NASDAQ: BIIB) shares shed close to 10% Wednesday following the revelation that the BLA filing for the company's Alzheimer's investigational drug aducanumab will be delayed. The Biogen Analysts Barclays analyst Carter Gould maintained an Overweight rating on Biogen...

Galera Therapeutics Inc (NASDAQ: GRTX), a biopharma company working on novel therapeutics for transforming radiotherapy treatment in cancer, recently IPO'd, offering 5 million shares at $12 apiece. Following the expiry of the IPO quiet period, Citigroup analyst Yigal Nochomovitz initiated...

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) are down about 1.8 percent on Monday trading, ahead of the announcement of the company’s second quarter financial results, scheduled for after the market closes on Tuesday. According to Estimize, experts are projecting earnings of $2.64 per...